ACOR

Acorda Therapeutics, Inc. News Headlines

$43.75
*  
0.20
0.46%
Get ACOR Alerts
*Delayed - data as of Jan. 23, 2015  -  Find a broker to begin trading ACOR now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Acorda Therapeutics, Inc. (ACOR): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report
1/17/2014 7:00:01 AM - Zacks.com


ACOR Preliminary Q4 Revs Look Good - Analyst Blog
1/14/2014 11:40:01 AM - Zacks.com


Positive Data on Incyte's Jakafi - Analyst Blog
12/10/2013 5:23:49 PM - Zacks.com


Another R&D Failure for Eli Lilly - Analyst Blog
12/6/2013 11:05:29 AM - Zacks.com


MDCO Acquires Rempex - Analyst Blog
12/5/2013 11:05:28 AM - Zacks.com


BioDelivery Sciences (BDSI) in Focus: Stock Adds 10.9% in Session - Tale of the Tape
12/4/2013 8:37:01 AM - Zacks.com


Biogen's Hemophilia B Drug Approval Delayed - Analyst Blog
12/3/2013 4:50:01 PM - Zacks.com


Dendreon Narrows Loss, Provenge Disappoints Again - Analyst Blog
11/15/2013 9:50:01 AM - Zacks.com


Chelsea Therapeutics (CHTP) Worth Watching: Stock Surges 11% - Tale of the Tape
11/12/2013 9:04:01 AM - Zacks.com


Cramer's Mad Money - Twitter May Be Hotter Than Facebook (11/5/13)
11/6/2013 5:46:00 AM - Seeking Alpha


Acorda Down on Q3 Earnings - Analyst Blog
11/4/2013 9:35:27 AM - Zacks.com


Ahead Of Earnings: Acorda Therapeutics, Boyd Gaming, Barrick Gold And Advance Auto Parts
10/30/2013 9:27:00 AM - Seeking Alpha


A Compulsion For Brain Science: Zack Lynch
10/18/2013 9:43:00 AM - Seeking Alpha


Acorda's Label Expansion Efforts - Analyst Blog
10/16/2013 12:10:01 PM - Zacks.com


Acorda's GGF2 in Another Study - Analyst Blog
10/14/2013 4:46:00 PM - Zacks.com


Acorda Therapeutics: 40% Upside Potential With Limited Downside Risk
10/14/2013 8:12:00 AM - Seeking Alpha


Biotech Stocks Continue Recent Downtrend; Ariad Tumbles to Lowest Price in Nearly Three Years
10/9/2013 11:40:01 AM - MT Newswires


Acorda Progresses with Pipeline - Analyst Blog
9/30/2013 10:41:57 AM - Zacks.com


Acorda Misses on Earnings by a Penny - Analyst Blog
8/5/2013 8:07:49 AM - Zacks.com


A Closer Look At Acorda's Post Commercial Stage Strategy
7/12/2013 3:20:00 AM - Seeking Alpha


Acorda Expands Pipeline - Analyst Blog
7/11/2013 5:56:44 PM - Zacks.com


Data on Acorda Pipeline Candidate - Analyst Blog
6/27/2013 3:32:52 PM - Zacks.com


2 Buys, 1 Sell In This Year's Biotech Surge
5/30/2013 8:00:00 AM - Seeking Alpha


Additional Patent for Acorda's Ampyra - Analyst Blog
5/22/2013 2:25:51 PM - Zacks.com


Acorda Therapeutics, Inc. (ACOR): Today's Most Compelling Stock Buy
5/13/2013 11:15:25 AM - David Moenning